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Abstract—Background: Electronic medical records (EMRs) are used in large healthcare centers
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to increase efficiency and accuracy of documentation. These databases may be utilized for
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clinical research or to describe clinical practices such as medication usage. Methods: We
conducted a retrospective analysis of EMR data from a headache clinic to evaluate clinician
prescription use and dosing patterns of topiramate. The study cohort comprised 4833 unique deidentified records, which were used to determine topiramate dose and persistence of treatment.
Results: Within the cohort, migraine was the most common headache diagnosis (n = 3753,
77.7%), followed by tension-type headache (n = 338, 7.0%) and cluster or trigeminal autonomic
cephalalgias (n = 287, 5.9%). Physicians prescribed topiramate more often for subjects with
migraine and idiopathic intracranial hypertension (IIH) (p < 0.0001) than for those with other
conditions, and more often for subjects with coexisting conditions including obesity, bipolar
disorder, and depression. The most common maintenance dose of topiramate was 100 mg/day;
however, approximately 15% of subjects received either less than 100 mg/day or more than 200
mg/day. More than a third of subjects were prescribed topiramate for more than 1 year, and
subjects with a diagnosis of migraine were prescribed topiramate for a longer period of time than
those without migraine. Conclusions: Findings from our study using EMR demonstrate that
physicians use topiramate at many different doses and for many off-label indications. This
analysis provided important insight into our patient populations and treatment patterns.

Deleted: the use of
Deleted: has not been fully evaluated
Deleted: To explore EMR as a clinical
research tool and determine the use of
topiramate and factors related to its use,
we conducted a retrospective analysis
from EMR data collected at the Jefferson
Headache Center in Philadelphia.
Deleted: for the

Marmura / 4
Introduction. Electronic Medical Records (EMRs) have the potential to improve clinical
efficiency and documentation. Recently, health care providers have begun using EMRs for
clinical research. Most large-scale retrospective observational studies conducted to date have
been based on insurance claims data (e.g., prescriptions filled to determine commonly prescribed
doses of a medication).1 EMRs vary widely in their structure, capacity, and extent of data
capture. Analysis is most successful in evaluating objective data, such as lab results. Subjective
or complex variables can be more challenging to measure and document. Results from clinical
practice may vary tremendously compared with the results of clinical trials. EMRs do not solve
all issues with documentation; they can help standardize documentation but do not prevent
inaccuracies.2 Most EMRs in clinical practice are designed to increase the accuracy of billing,
eliminate the need for dictation, improve communication of health information between
clinicians, and prevent errors rather than for use as a research tool.
Retrospective EMR analyses have yielded important findings that can affect clinical care, such as
studies showing increased cardiovascular event rates with the use of rofecoxib.3 Other EMR
studies have documented prevention of medication errors4 and demonstrated trends in treatment
response that may lead to better practice. For instance, a recent EMR analysis demonstrated that
antiepileptic usage in elderly patients has not changed significantly despite changes in clinical
guidelines.5 EMR studies can also help determine compliance with treatment guidelines and
demonstrate cost savings.6 The goal of this pilot study was to explore the utility of EMR as a
clinical research tool through an evaluation of patient demographics, diagnoses, and topiramate
use in a cohort of patients treated at a university-based headache specialty clinic.
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Methods. This study was a retrospective analysis of de-identified, aggregate EMR data from the
Jefferson Headache Center in Philadelphia, Pennsylvania. A waiver of authorization for use of
personal health information and Institutional Review Board approval was obtained.
The Jefferson Headache Center utilizes Centricity® Physician Office (formerly Logician) to
document and maintain patients’ medical records. All unique records with an initial office visit
from April 1, 2000 through June 30, 2006 were evaluated and categorized into two patient
groups: those who had received at least one prescription order for topiramate during the study
period, and those who had not. The no topiramate group included patients who were never
prescribed topiramate, or whose prescription start and stop date occurred before the study period,
had an order entered and removed the same day, or had only a single order with instructions to
taper off topiramate. All records have a clinical date-time stamp that is independent of the
physician or nurse user. There are no required fields; the EMR system and documentation are
driven by clinical care. The patient identifiers are system-generated markers that maintain related
records. Medical diagnoses were recoded using both the ICD-9-CM code and description.
Conditions that might influence topiramate use were examined, including diabetes, hypertension,
obesity, epilepsy, anxiety, depression, bipolar disorder, tremor, and fibromyalgia.
To ascertain dose and length of time on topiramate, tables containing the medication description
(product name, dose form, strength) and instructions for each patient were merged with tables of
prescription quantities, refills, and associated medication order key. The type of prescription,
date, and time that the prescription was written were used to remove duplicates, and all
prescription reprints were deleted. When there were multiple prescriptions for the same order on
the same date with different pill quantities, the latest timed orders were retained. Maintenance
dose was defined as the daily dose ordered for the longest total period of time. The start date for
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determining total persistence of treatment was the first order date. If a patient had a documented
stop date, it was used as the end date, and no further calculation was done. In instances where a
patient did not have a documented stop date, the end date was calculated based on the last
prescription date plus the pill supply days. We assumed the medication was taken as directed.
Statistical methods. Analyses were conducted on the entire study group (patients with and
patients without a topiramate prescription order) and then separately within the group of patients
with topiramate prescription orders. Descriptive statistics such as means, medians, and
frequencies between groups were calculated for age, race, gender, marital status, diagnoses,
number of office visits, and contact time. Significance was tested using the Pearson chi-square
test for categorical outcomes; the t-test or Wilcoxon two-sample test were used for continuous
outcomes. Variables with a time dimension, such as persistence on topiramate, were analyzed
separately by year. Within the group of patients with topiramate prescription orders, medication
usage was similarly explored based on diagnoses, such as migraine or cluster headache. Simple
logistic regression was used to determine any associations between patient factors (such as
diagnosis) and topiramate use. Significance was assessed using the Wald Chi-squared statistic.
No adjustments for multiplicity were made due to the exploratory nature of this study. Statistical
analyses were done using SAS 9.1 (SAS Institute, Cary, NC).
Results. We extracted 4833 unique records with an initial visit during the study period of April
1, 2000 through June 30, 2006. Study demographics are summarized in Table 1; most patients
Formatted: Highlight

were white, female, and married at the time of the study. Race, gender, and age were all
significantly associated with a topiramate prescription order but these results were complicated
by missing data. Race was a missing field for 376 patients and 122 had no listed martial status.
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Subjects with a topiramate order were on average 2.65 years younger than nonusers (mean age ±
SD: 39.30 ± 12.63 vs 41.95 ± 15.99, p < 0.001).
The median number of clinic visits was six, and the mean visit number per record was eight.
Patients who received prescription orders for topiramate had a greater number of clinic visits,
with a median of nine, compared with a median of three visits for those without a topiramate
order (p < 0.001). Patients who received topiramate continued their care at the Jefferson
Headache Center for longer than those who did not (median: 378.5 days vs 63 days; p < 0.001).
Diagnoses. Patients evaluated at the Jefferson Headache Center were found to have diagnoses in
22 different categories. Primary headaches were most common, and migraine was the most
common headache type: migraine (n = 3753; 77.7%), tension-type headache (n = 338; 7.0%),
and cluster or trigeminal autonomic cephalalgias (n = 287, 5.9%). Secondary headache
diagnoses, either alone or in addition to a primary headache diagnosis, were common (n = 1413;
29.2%) and included cervicalgia, post-traumatic headache, idiopathic intracranial hypertension
(IIH), tumor, cerebrovascular accident, or aneurysm. A total of 2443 (50.5%) patients had
multiple headache diagnoses. The most common diagnosis combinations were: chronic migraine
and medication overuse headache (n = 558, 11.5%), migraine without aura and chronic migraine
(n = 512, 10.6%), migraine with and without aura (n = 304, 6.3%), and migraine with aura and
chronic migraine (n = 285, 5.9%).
At the Jefferson Headache Clinic, most prescription orders for topiramate were for patients with
a diagnosis of migraine. Physicians ordered topiramate more often for patients with a diagnosis
of migraine or IIH and less often for patients with tension headache, cluster headache, or cranial
neuralgias such as trigeminal neuralgia. Patients who were overweight or obese, had bipolar
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disorder, depression, seizures, tremors, or fibromyalgia received a prescription order for
topiramate more frequently than the rest of the patient cohort (Table 2).
Dosing. Topiramate was prescribed at doses ranging from as low as 15 mg every other day to as
high as 1600 mg per day. Figure 1 shows the distribution of 2192 patients who received a dose of
topiramate, by the maintenance and maximum daily topiramate dose. Maintenance dose was
defined as the dose prescribed for the longest period of time during the study. The most
frequently prescribed maintenance dose was 100 mg/day (n = 750, 34.2%). Our findings also
revealed that 329 (15.0%) patients were prescribed a maintenance dose less than 100 mg/day and
332 (15.1%) patients were prescribed a maintenance dose greater than 200 mg per day. The
median topiramate daily dose (125 mg) was the same in migraine and non-migraine patients. The
median topiramate daily dose (100 mg) was not significantly different in patients with tensiontype headache than patients without a diagnosis of tension-type headache (125mg). IIH was the
only headache diagnosis for which the median maintenance daily dose was higher than those
with all other headache diagnoses. (200 mg vs 125 mg; p = 0.0106).
Many factors can influence the dosing of topiramate, including the headache diagnosis and
coexisting medical conditions. Patients with a diagnosis of migraine, particularly chronic
migraine, were significantly more likely to have a diagnosis of depression. Of the 3753 patients
in the “All migraine” category, 1241 (33%) also had a diagnosis of depression (odds ratio [OR],
1.21; 95% confidence interval [CI], 1.04 to 1.40; p = 0.0114), and of the 2265 patients in the
“chronic migraine” category, 945 (41.7%) also had a diagnosis of depression (OR, 2.30; 95% CI,
2.04 to 2.61; p = <0.001). Patients with depression taking topiramate (830 of 1554 patients,
53.4%) received a higher median daily dose than patients without a diagnosis of depression (150
mg vs 100 mg; p = 0.0272). On the other hand, patients with anxiety disorders who were
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prescribed topiramate (505 of 1053 patients, 48.0%) received a lower median topiramate dose
than patients without the diagnosis (100 mg vs 150 mg; p = 0.0372). One hundred and fifteen of
158 (72.8%) patients with an overweight or obesity diagnosis were prescribed topiramate and
received a higher median daily dose of topiramate compared with patients without a diagnosis of
being overweight or obese, but this was not significant (150 mg vs 125 mg; p = 0.1583).
Persistence of treatment. Persistence of topiramate treatment was similar whether computed by
the period patients took topiramate, based on prescription order data or by projection from the
amount of pills taken. Figure 2 shows the proportion of patients and the total time that patients
took topiramate. More than one third of all patients took topiramate for more than 1 year. Of the
2192 patients who received topiramate during the study period, 2098 had at least two orders or
one order and a prescription, allowing a dimension of persistence on the drug to be calculated.
Six hundred and eighty three of the 2098 (32.6%) patients had topiramate on their current
medication list and had a prescription in the final 6 months of the study. In all years during the
study period, most patients who received topiramate, had a diagnosis of migraine. During the
entire study period (2000-2006), patients with migraine remained on topiramate an average of
108 days longer than patients without migraine. Persistence was longer for patients with
migraine who began therapy in the years 2001, 2003, 2004, and 2005 (p = 0.0349, 0.0192,
0.0346, and 0.0144), and marginally so for patients who began taking topiramate in 2002 (p =
0.0781), compared with patients without a diagnosis of migraine (table 3).
Discussion. This study provides insight into the usefulness of EMR as a clinical research tool
through an assessment of how practitioners at a university referral center used topiramate in
everyday clinical practice for the treatment of patients with headache. Results indicate that
clinicians at the headache center prescribe topiramate to treat many different types of headaches.
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Topiramate is approved by the United States Food and Drug Administration (FDA) for the
prevention of migraine in adults, so it is not surprising that physicians at the headache center had
prescribed topiramate for nearly half of the patients in the study population. Patients who were
younger, female, and white were more likely to have received topiramate, probably because
these patients were more likely to have a diagnosis of migraine and chronic migraine than those
in the no topiramate group. Providers were more likely to prescribe topiramate during treatment
for patients with more clinic visits, possibly because the headache center’s physicians tend to
prescribe topiramate more often for cases of refractory headache. Our EMR does not require
physicians to distinguish between chronic and episodic migraine, and many patients have both a
chronic and episodic diagnosis, as patients often improve or worsen with treatment. This makes
it difficult to determine if different doses are needed for those with chronic migraine.
In our study, topiramate was prescribed for uses that have not been approved by the FDA, such
as IIH. Recent studies have shown topiramate to be effective for IIH.12,13 Many patients with
secondary headaches, cluster headache, and cranial neuralgias also received topiramate. Some
small studies have shown that topiramate can be helpful for patients with trigeminal
neuralgia14,15 or cluster headache.16 Our study also indicates that topiramate was more likely to
have been prescribed for patients with coexisting medical diagnoses such as depression, bipolar
disorder, and obesity. This finding could be related to the fact that depression and bipolar
disorder are co-morbid conditions in chronic migraine; while obesity has been implicated as a
risk factor for developing chronic migraine.17 Physicians may also have prescribed topiramate
with the hope of inducing weight loss in obese patients.
The variability of the daily doses of topiramate in the study was notable. Physicians prescribed,
on average, higher doses of topiramate for patients with chronic migraine or IIH. Clinical studies
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to date have used daily doses of 200 mg or less for migraine prevention. In a study of patients
with episodic migraine, topiramate 200 mg/day was no more effective than 100 mg/day.18 In
contrast, a minority of patients seen at the Jefferson Headache Clinic received doses higher than
200 mg/day, perhaps because they metabolized the medication more efficiently, were more
resistant to medication-related side effects, and/or had conditions that were less responsive to
usual treatment. Other patients received daily doses less than 100 mg, often for extended periods
of time. Paresthesias, a common topiramate side effect, may be bothersome to anxious patients,
and may explain why they tend to be on lower doses. The study emphasizes the importance of
individualizing treatment.
Headache classification and practice evolved over the specified study period, leading to an
increasing tendency for physicians to enter more than one headache diagnosis into the EMR. For
example, the diagnosis of transformed migraine was initially cited on the headache center’s
custom list as “transformed migraine with and without rebound”, a combination of two distinct
diagnoses. The diagnoses were eventually separated and, for the “with rebound” diagnosis
segment, the nomenclature was changed to medication overuse headache to align with new
diagnostic terminology. Moreover, many patients with a diagnosis of migraine received
additional diagnoses, such as cervicalgia, tension headache, or cervical dystonia, to reflect these
coexisting conditions and their possible contribution to the clinical presentation of the patient’s
migraine disorder. This practice increased as billing documentation requirements became more
rigorous. One issue related to this change in documentation is that multiple diagnoses make it
difficult to determine the primary reason which motivated the patient to seek treatment; EMR
does not require clinicians to list the most significant illness first.
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Using EMR data for the various clinical analyses provided useful information regarding patient
characteristics, diagnoses, coexisting medical conditions, and treatment patterns, but organizing
and analyzing these data presented numerous challenges. Limitations in interpreting the results
include the fact that most EMR systems are primarily used for billing and clinical practice
documentation rather than research purposes. EMRs used for clinical practice purposes do not
require the same degree of monitoring and visit-to-visit consistency that is usually required in
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traditionally designed clinical trials. The EMR analyzed in this study had no required fields, and
important data fields basic to research, such as race or marital status, often had missing data. In
clinical practice, an EMR with required fields places an added time burden on clinicians, but this
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lack of required data makes research more difficult. Although some patients follow up at regular
intervals, others may visit the clinic more often when they are not doing well and only
sporadically when they are feeling better. In addition, physicians and healthcare systems tend to
vary in their documentation styles. For instance, because most patients at the Jefferson Headache
Clinic are required to see a mental health provider, better availability of psychiatric diagnoses in
the EMR would be expected. Many medical diagnoses were underrepresented because of the
specialty focus of the clinicians at the headache center. Although patients fill out a questionnaire
before their initial visit with a past medical history, a diagnosis is only listed in the EMR if a
nurse or physician enters the diagnosis. The EMR does not automatically generate diagnoses
based on data such as height and weight, so obesity in this cohort was greatly underdiagnosed
due to fact that many providers did not enter the diagnosis in the EMR. Similarly, we believe that
fibromyalgia, a co-morbid condition reportedly found in more than 20% of female patients with
migraine, was likely underdiagnosed.19
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The data in fields for medication and dosing were also often incomplete or difficult to analyze.
For example, a prescription might have had unclear directions for administration, such as “taper
as directed,” requiring assumptions to be made about the intended dose. Moreover, physicians
may not have documented the dispensing of drug samples to patients, perhaps affecting the
initial dose and persistence analyses. In addition, patients received multiple prescriptions at the
same visit. For instance, a physician would prescribe a 1-month supply of medication with three
refills, but the patient would subsequently request a 90-day prescription for mail order drug
delivery, which led to entry of new prescription data into the EMR. Some repeat EMR order
entries were obvious, but others required manual review of the EMR to determine the actual
intended dose. Finally, we needed to make assumptions about patients who lapsed in their clinic
treatment. Clinic policy is not to refill prescriptions without a visit within the year.
Discontinuation was assumed, but manual review revealed that some patients who stopped
taking topiramate did so because their headaches improved, they were planning to become
pregnant, or they did not make a clinic visit for an extended period. Some patients continued to
receive topiramate from an outside provider, and others stopped the medication only to resume it
later. Additionally, the study end date placed a false stop time on those who received additional
prescriptions.
Another assumption was that patients took their medication as prescribed, but many patients fail
to take prophylactic medication for adequate lengths of time. Based on data from pharmacy
claims, more than half of patients discontinue migraine prophylactic treatment by two months.
The rate of topiramate treatment persistence at 2 months in one study was 46.4%, and the
treatment persistence of other common preventatives such as amitriptyline (34.1%) and
divalproex sodium (42.7%) were even lower. 20
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This pilot study extracted and analyzed data from the EMR system used at the Jefferson
Headache Center. The consistency of staff and practice patterns within the Headache Center is
believed to have strengthened this study’s findings. Although the results can be useful for
examining practice patterns and treatment trends at the Jefferson Headache Center, they cannot
be generalized to all medical or headache specialty practices because of variability in patient
populations and local standards of care. Likewise, the utility of this clinical research method and
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its findings cannot be generalized to all EMR systems, because of wide variability in system
structure and format. This research study required funding and extensive review to validate the
findings and understand the discrepancies. These are luxuries that are not available to the
average office practice. Dedicated effort and resources to understand the clinical information
available in EMRs may be underestimated or underreported. Overall, the utility of EMRs for
research would be enhanced by the standardization of EMR system design. If standardized,
EMRs could be a useful tool for evaluating patient populations, disease categories, treatment
patterns, and clinical outcomes within and across healthcare systems or local geographic regions.
With these insights, it might be possible to determine best practices as well as practices that
require improvement and ongoing monitoring. Without standardization and forethought in the
design or use of EMR systems, a number of limitations in the analysis of EMR data could have
the consequence of producing clinical information and outcome assessments that are difficult to
interpret and lack a reasonable level of confidence.
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Table 1 Demographics
Received topiramate

Did not receive topiramate

(n = 2192)

(n = 2641)

Formatted Table

Demographics

p value

n

%

n

%

White

1933

93.43

2185

91.50

Non-white

136 *

6.57

203 **

8.50

Race (n = 4457)
<0.001#

Deleted: ,

* (Black 105, Hispanic 18, Native American 2, Asian 5, Other 6)
** (Black 128, Hispanic 16, Native American 5, Asian 34, Other 20)
Undetermined

376

Gender
Female

1763

80.43

1831

69.33

Male

429

19.57

810

30.67

Married

1261

58.54

1409

55.78

Not married

893 ***

41.46

1117 ***

44.22

<0.001#

Marital status (n = 4680)
0.0571

*** (Separated 19, Divorced 113, Single 742, Other 2, Widowed 17)
**** (Separated 23, Divorced 134, Single 886, Other 9, Widowed 65)
Formatted: Indent: Left: 0.18"

Undetermined

122

Formatted: Left

Age
Mean ± SD
Median
Min, max

39.30 ± 12.63

41.95 ± 15.99

39.83

41.17

12.45, 86.34

13.31, 90.22

<0.001†
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#

p values derived by the χ2 test.

†

p value derived by the t-test.
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Table 2 Association of topiramate prescription by broad headache category and co-existing
diagnoses
Total

Patients on

95%
Odds

number of

topiramate

Confidence

p value

ratio*
patients

(%)

Migraine

3753

1832 (48.8)

1.91

(1.66, 2.20)

<0.0001

Tension

338

103 (30.47)

0.51

(0.40, 0.64)

<0.0001

Cluster

269

100 (37.17)

0.70

(0.54, 0.90)

NS

Other primary and NOS

869

397 (45.68)

1.02

(0.88, 1.18)

NS

Secondary (post-traumatic and

1164

553 (47.51)

1.12

(0.98, 1.28)

NS

Post-traumatic

181

78 (43.09)

0.91

(0.67, 1.23)

NS

IIH

178

135 (75.84)

3.97

(2.80, 5.62)

<0.0001

Cranial neuralgias

161

56 (34.78)

0.63

(0.46, 0.88)

0.0066

Diabetes

78

38 (48.72)

1.15

(0.73, 1.80)

NS

Overweight and obesity

158

115 (72.78)

3.34

(2.34, 4.77)

<0.0001

Anxiety and panic

1053

505 (47.96)

1.14

(1.00, 1.31)

NS

Bipolar

186

113 (60.75)

1.91

(1.42, 2.58)

<0.0001

Depression

1554

830 (53.41)

1.61

(1.43, 1.82)

<0.0001

Seizures

76

46 (60.53)

1.87

(1.17, 2.97)

0.0084

Fibromyalgia

115

70 (60.87)

1.90

(1.30, 2.78)

0.0009

Interval

Diagnostic category

IIH excluded)

Co-existing diagnosis
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Tremors

51

34 (66.67)

2.43

(1.36. 4.37)

0.0029

*Odds ratios were calculated using simple logistic regression, and p values are the associated p
values from the Wald Chi square tests associated with those univariate models.
IIH = idiopathic intracranial hypertension; NOS = not otherwise specified.
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Table 3 Total persistence on topiramate during study period by year and migraine status
Median number of days
Year

Migraine status Number of patients

p value*
(min, max)

No

28

251.5 (28,2295)

Yes

94

399.5 (26,2263)

No

54

146 (14,1924)

Yes

215

300 (15,1927)

No

46

259 (15,1480)

Yes

299

388 (1,1639)

No

55

212 (7,1214)

Yes

288

334 (10,1271)

No

52

139.5 (27,844)

Yes

332

272.5 (30,899)

No

70

166.5 (21,506)

Yes

369

212 (6,543)

No

31

64 (19,163)

Yes

164

90 (1,177)

NS

2000

0.0349

2001

NS

2002

0.0192

2003

0.0346

2004

0.0144

2005

2006

*p values derived by the Wilcoxon test.

NS
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Figure 1. Distribution of patients taking topiramate by maintenance and maximum daily dose.
Maintenance dose is defined as the dose for the longest period of time during the study. All
patients were included regardless of length of treatment. A total of 2192 patient records were
evaluated.
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Figure 2. Persistence on topiramate based on the period patients took topiramate or projection
from the number of pills. Total number of patient records evaluated: study period, n = 2097;
number of pills, n = 2098.
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